Essential Hypertension
Conditions
Brief summary
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
Interventions
DRUGD064, D702, placebo of D660
Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
DRUGD660, placebo of D064, placebo of D702
Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects who are 19 years old or older. * Subjects who have voluntarily decided to participate in this clinical trial and signed ICF.
Exclusion criteria
1. Subjects with a history of secondary hypertension or suspected secondary hypertension 2. Subjects with hypersensitivity or history of clinical trial drugs and similar drugs 3. Subjects who are required to administer a combination of prohibited drugs specified in this plan during the clinical trial participation period 4. Subjects with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening 5. Subjects who received other clinical trial drugs within 4 weeks of screening visit. 6. Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug 7. Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in MSSBP | 8 weeks after drug administrations | MSSBP(Mean Sitting Systolic Blood Pressure) |
Countries
South Korea
Outcome results
None listed